Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) saw a downside of -47.57% to close Monday at $0.43 after subtracting -$0.39 on the day. The 5-day average trading volume is 1,216,720 shares of the company’s common stock. It has gained $1.0800 in the past week and touched a new high 2 times within the past 5 days. An average of 616,870 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 375,658.
BCLI’s 1-month performance is -72.05% or -$1.2323 on its low of $0.4277 reached on 09/25/23. The company’s shares have touched a 52-week low of $0.78 and high of $4.56, with the stock’s rally to the 52-week high happening on 03/31/23. YTD, BCLI has lost -73.92% or -$1.2123 and has reached a new high 13 times. However, the current price is down -90.62% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
BCLI stock has a beta of -0.36.
Brainstorm Cell Therapeutics Inc.’s quick ratio for the period ended June 30 was 0.16, with the current ratio over the same period at 0.16.
Earnings Surprise
For the quarterly period ending June 30 this year, Net income shrunk -32.08% to -$5.33 million, while revenue of -$5.06 million was 5.07% off the previous quarter. Analysts expected BCLI to announce -$0.15 per share in earnings in its latest quarter, but it posted -$0.27, representing a -80.00% surprise. BCLI stock balance sheet for the quarter ending June 30 shows that total liabilities totaled 9.63 million, with total debt at $3.29 million. Shareholders hold equity totaling $45.02 million.
Let’s look briefly at Brainstorm Cell Therapeutics Inc. (BCLI) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 25 September was 7.90% to suggest the stock is trending oversold, with historical volatility in this time period at 287.65%.
The stock’s 5-day moving average is $0.8348, reflecting a -57.01% or -$0.5671 change from its current price. BCLI is currently trading -74.23% above its 20-day SMA, -85.74% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -78.29% and SMA200 by-72.76%.
Stochastic %K and %D was 2.90% and 3.37% and the average true range (ATR) pointed at 0.1675. The RSI (14) points at 12.65%, while the 14-day stochastic is at 0.00% with the period’s ATR at 0.1583. The stock’s 9-day MACD Oscillator is pointing at -0.2103 and -0.3774 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), Maxim Group upgraded it to a Buy rating. They previously had a Hold rating on the stock. Analysts offering their rating for BCLI stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate BCLI as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 1 have offered a “buy” rating.
What is BCLI’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $10.00 and a high of $20.00, with their median price target at $15.00. Looking at these predictions, the average price target given by analysts is for Brainstorm Cell Therapeutics Inc. (BCLI) stock is $15.00.
